TGFB1 and neoplasm: More recently, Schoonderwoerd et al. reported that Abs for endothelin, a coreceptor for TGF-β ligands, significantly decreased the number of intratumoral Tregs, leading to enhanced anti-tumor immune response with anti-PD1 Ab therapy [52].